Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study

Clinical Infectious Diseases

Volumn 51, Issue 8, 2010, Pages 963-972

  Stellbrink, Hans Jürgen ^a   Orkin, Chloe ^b   Arribas, Jose Ramon ^f   Compston, Juliet ^e   Gerstoft, Jan ^g   Van Wijngaerden, Eric ^h   Lazzarin, Adriano ⁱ   Rizzardini, Giuliano ^j   Sprenger, Herman G ^k   Lambert, John ^l   Sture, Gunta ^m   Leather, David ^c   Hughes, Sara ^d   Zucchi, Patrizia ⁿ   Pearce, Helen ^c  

^a Epilepsy Center Hamburg   (Germany)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d VIIV HEALTHCARE   (United States)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^g Rigshospitalet   (Denmark)

^h UNIVERSITY HOSPITALS LEUVEN   (Belgium)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

^j UNIVERSITY OF MILAN   (Italy)

^k UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^l MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^m Latvijas Infektologijas Centrs   (Latvia)

ⁿ GSK   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ALKALINE PHOSPHATASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; OSTEOCALCIN; PROCOLLAGEN;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EXPLORATORY RESEARCH; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ABSORPTIOMETRY, PHOTON; ADENINE; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; BONE AND BONES; BONE DENSITY; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; EUROPE; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; YOUNG ADULT;

EID: 77957847133     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656417     Document Type: Article

References (36)

1. European AIDS Clinical Society. Guidelines for the clinical management and treatment of HIV infected adults in Europe. 2008. http://www. europeanaidsclinicalsociety.org/guidelines.asp. Accessed 25 March 2010.
2. Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society- USA panel. JAMA 2006; 296(7):827-843.
3. Hetherington S, McGuirk S, Powell G, et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin Ther 2001; 23:1603-1614.
4. Hernandez JE, Cutrell A, Edwards M, et al. Clinical risk factors for hypersensitivity reactions to abacavir: retrospective analysis of over 8,000 subjects receiving abacavir in 34 clinical trials [abstract H2013]. Presented at the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 13-17 September 2003, Chicago IL.
5. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
6. Sabin CA, Worm SW, Weber R, et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 2008; 371(9622):1417-1426.
7. Brothers CH, Hernandez JE, Cutrell AG, et al. Risk of myocardial infarction and abacavir therapy: no increased risk across GlaxoSmithKline- sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51(1):20-28.
8. Kivexa summary of product characteristics, 20 May 2010. http://emc.medicines.org.uk.
9. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
10. Martin A, Bloch M, Amin J, et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49(10):1591-1601.
11. Parsonage MJ, Wilkins EGL, Snowden N, et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy. HIV Medicine 2005; 6(5): 341-346.
12. Fux C, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antiviral Therapy 2008; 13(8):1077-1082.
13. Hansen A-BE, Pedersen C, Nielsen H, et al. Bone mineral density (BMD) changes until week 144 in a randomised trial of protease-inhibitor- sparing versus nucleoside-analogue-sparing HAART. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa.
14. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14(10):F63-F67.
15. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20(17): 2165-2174.
16. Calmy A, Fux CA, Norris R, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200(11):1746-1754.
17. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004; 19(3):402-409.
18. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36(4):482-490.
19. Duvivier C, Kolta, S, Assoumou L, et al. Greater decrease in bone mineral denisity with protease inhibitor regimens compared with nonnucleaoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23:817-824.
20. Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93(9):3499-3504.
21. Van Vonderen MG, Lips P, van Agtmael MA, et al First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS 2009; 23(11):1367-1376.
22. Brown TT, McComsey GA, King MS, et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51(5):554-561.
23. McComsey G, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomised, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [abstract 106LB]. Presented at the 17th Conference on Retroviruses and Opportunistic Infections, 16-19 February 2010, San Francisco, California.
24. Leeming DJ, Alexandersen P, Karsdal MA, et al. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. Eur J Clin Pharmacol 2006; 62(10):781-792.
25. Szulc P, Delmas PD. Biochemical marker of bone turnover: potential use in the investigation and management of postmenopausal osteoporosis. Osteoporosis International 2008; 19(12):1683-1704.
26. Eriksen EF, Melsen F, Mosekilde L. Histomorphometric analysis of resorption and formation in osteoporotics and controls with a mean age of 61 years. J Bone Miner Res 1992; 7(8):999-1002.
27. Post F, Moyle G, Stellbrink H-J, et al. Once daily abacavir-lamivudine versus tenofovir-emtricitabine, administered with efavirenz, in anti-retroviral-naive, HIV-1 infected adults- 48-week results from the prospective, randomized ASSERT Study. J Acquir Immune Defic Syndr 2010; 55(1):49-57.
28. Binkley N, Bilezikian JP, Kendler DL, Leib ES, Lewiecki EM, Petak SM; International Society for Clinical Densitometry. Official positions of the International Society for Clinical Densitometry and Executive Summary of the 2005 Position Development Conference. J Clin Densitom 2006; 9:4-14.
29. Grund B, Peng G, Gilbert CL, et al. Continuous antiretroviral therapy decreases bone mineral density. AIDS 2009; 23(12):1519-1529.
30. Chew NS, Doran PP, Powderly WG. Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Curr Opin HIV AIDS 2007; 2(4): 318-323.
31. Welz T, Childs K, Ibrahim F, et al. Efavirenz use is associated with severe vitamin D deficiency in a large ethnically diverse urban UK HIV cohort [abstract TUPEB186]. Presented at the 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 2009, Cape Town, South Africa.
32. Orwoll ES, Klein RF. Osteoporosis in men. Endocr Rev 1995; 16(1): 87-116.
33. Guthrie JR, Ebeling PR, Hopper JL, et al. A prospective study of bone loss in menopausal Australian-born women. Osteoporos Int 1998; 8(3):282-290.
34. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93(3):861-868.
35. Jacobson DL, Spiegelman D, Knox TK, et al. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008; 49:298-308.
36. Yin MT, Lu D, Cremer S, et al. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010; 53(2): 202-208.